Skip to content

Study · In vitro (cells) · 2010

3 results

Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.

Oztürk HB, Vural B, Calışkan E, Solakoğlu S

Journal of the Turkish German Gynecological Association1 Sept 2010Cited by 3 (Europe PMC)

PMID24591918 (opens in a new tab)PMCIDPMC3939219 (opens in a new tab)DOI10.5152/jtgga.2010.19 (opens in a new tab)PepBankPUB-24591918
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In grade III endometrial cancer cells, ganirelix increased TUNEL-positive cells compared with untreated controls.

    In plain wordsIn cells from grade III endometrial cancer, ganirelix increased cell death compared with untreated controls.

    Peptide
    Ganirelix
    Outcome
    IncreaseGrade III apoptotic cells
    Study

    humann: not reported in source

    Endometrioid endometrial cancer cell lines
    Comparator
    Untreated control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 μmol/LAs given in this study (human).

    Source sentences

    Summary
    In grade III EEC cell line, the number of TUNEL positive cells among leuprolide, ganirelix and ganirelixoctreotide therapiy groups were significantly higher than in untreated control.
    2 context sentences
    Summary · context
    Endometrium cancer cell lines obtained from three patients were used for this study.
    Summary · context
    GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells.
  2. 02LabIn vitro (cells)Efficacy outcome

    In grade II endometrial cancer cells, ganirelix did not affect proliferation compared with untreated controls.

    In plain wordsIn cells from grade II endometrial cancer, ganirelix did not affect cell multiplication compared with untreated controls.

    Peptide
    Ganirelix
    Outcome
    No significant changeGrade II proliferation
    Study

    humann: not reported in source

    Endometrioid endometrial cancer cell lines
    Comparator
    Untreated control
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 μmol/LAs given in this study (human).

    Source sentences

    Summary
    Grade II EEC cell line is not influenced by hormonotherapies.
    2 context sentences
    Summary · context
    GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells.
    Summary · context
    Endometrium cancer cell lines obtained from three patients were used for this study.
  3. 03LabIn vitro (cells)Efficacy outcome

    In grade III endometrial cancer cells, ganirelix had an antiproliferative effect.

    In plain wordsIn cells from grade III endometrial cancer, ganirelix reduced cell multiplication.

    Peptide
    Ganirelix
    Outcome
    DecreaseGrade III proliferation
    Study

    humann: not reported in source

    Endometrioid endometrial cancer cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 μmol/LAs given in this study (human).

    Source sentences

    Summary
    However, the antiproliferative effect was obtained with ganirelix, leuprolide and leuprolide-octreotide in grade III cell line.
    2 context sentences
    Summary · context
    Endometrium cancer cell lines obtained from three patients were used for this study.
    Summary · context
    GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.